Floatz logo

Trifluridine/Tipiracil Hydrochloride Combination Agent Tas-102

Metastatic Colon Cancer

University of Campania Luigi VanvitelliunclassifiedPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

34 Active assets in the Metastatic Colon Cancer cohort.

Asset / SponsorPhaseRating
Eloxatin
Fudan University
Phase 4BBB
Fruquintinib
Peking University
Phase 3BBB
DEXAMETHASONE
Fudan University
Phase 3BB
Capecitabine
Jun Huang
Phase 3BB
Irinotecan
Jun Huang
Phase 3BB

View all 50 →

Same molecule, other indications

Trifluridine/Tipiracil Hydrochloride Combination Agent Tas-102 is also rated in:

colorectal neoplasmDormant
B
Indicative ·
57 / 100
View asset →
Advanced Microsatellite Stable Colorectal CancerDormant
CCC
Indicative ·
53 / 100
View asset →
anal carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →